Nkarta Q2 FY26 net loss widens to $40.4 million
NKTX•Q2 results and cash position
- Nkarta posted a net loss of $40.4 million, or $0.54 per share, for Q2 2026.
- R&D expense totaled $29 million, while G&A expense was $14.1 million.
- Cash, cash equivalents, restricted cash, and investments were $243.2 million at June 30, expected to fund operations into 2029.
- Enrollment continued in Ntrust-1 and Ntrust-2 at the 4 billion cell dose level; outpatient dosing began at community-based sites.
- Initial clinical data from Ntrust-1 and Ntrust-2 are planned for presentation at a medical conference in 2026.
Related News
IBM Prices C$2.75B In Canadian Notes C$1.75B Due 2030 At 4.100%, C$1.00B Due 2034 At 4.750%
IBM•
Grupo Supervielle returns to profit in 2Q FY26 with AR$ 12.8 billion net income; net financial income rises 8.3% QoQ to AR$ 294.5 billion
SUPV•
